stay tuned:
elixi news from the
world

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes

First Cellular Therapy to Treat Patients with Type 1 Diabetes has been approved by FDA.
It is the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes.
“Severe hypoglycemia is a dangerous condition that can lead to injuries resulting from loss of consciousness or seizures,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval, the first-ever cell therapy to treat patients with type 1 diabetes, provides individuals living with type 1 diabetes and recurrent severe hypoglycemia an additional treatment option to help achieve target blood glucose levels.”
Visit FDA.gov for the full press release #diabetes #diabetessupport

Share this article

Tweet
Share
Pin it
Share

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter

    Headquarter

    Elixi International SA
    Vicolo Oldelli 12
    6830 Chiasso (TI)

    Switzerland

    Tel.  +41 (0)91 6822040
    info@elixi-int.com

    Subsidiary

    Elixi Europe Srl
    Via Uberti 6
    21100 Varese (VA)

    Italy

    Tel.  +41 (0)91 6822040
    europe@elixi-int.com

    Subsidiary

    Elixi Pharma pte. ltd.
    16 Raffles quay #33-03
    Hong Leong building

    Singapore

    Tel.  +41 (0)91 6822040
    singapore@elixi-int.com

    ELIXI International SA

    Copyright 2023 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy